Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
(42 sites) Australia
Chris O'Brien Lifehouse, Camperdown, New South Wales Nepean Hospital, Penrith, New South Wales Royal North Shore Hospital, St Leonards, New South Wales Princess Alexandra Hospital, Woolloongabba, Queensland Flinders Medical Centre, Bedford Park, South Australia Royal Hobart Hospital, Hobart, Tasmania Eastern Health, Box Hill, Victoria Alfred Hospital, Melbourne, Victoria Peter MacCallum Cancer Centre, Parkville, Victoria Sir Charles Gairdner Hospital, Nedlands, Western Australia Belgium
Institut Jules Bordet - HUB, Anderlecht Antwerp University Hospital, Antwerp Estonia
North Estonia Medical Centre Foundation, Talinn France
Institut Bergonié, Bordeaux Lyon - Centre Léon Bérard, Lyon Ireland
Beaumont Hospital, Dublin St James's Hospital, Dublin Italy
SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria Istituto Oncologico Veneto, Padova Perugia Hospital, Perugia Istituto Nazionale Tumori "Regina Elena", Rome AOUS Policlinico Le Scotte, Siena Universita di Verona - Department of Medicine, Verona Switzerland
Kantonsspital Baden, Baden Universitätsspital Basel, Basel HFR Hôpital Fribourgeois, Fribourg Kantonsspital St.Gallen, Sankt Gallen Kantonsspital Winterthur, Winterthur University Hospital Zurich, Zurich United Kingdom
Barts Health NHS Trust, London Royal Marsden Hospital (Chelsea), London Royal Marsden Hospital (Sutton), London Maidstone and Tunbridge Wells NHS Trust, Maidstone Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester